India's where this Sun shines, but US clouds worry investors
indiatimes.com
economics
2022-05-31 13:30:00

ET Intelligence Group: Sun Pharmaceutical Industries' fourth-quarter results reinforced investor faith in the company's progress on one hand, but on the other also raised doubts about whether it could deliver steady performance without any negative surprises. Net sales rose 11%, or at the lower end of Street's expectations. Growing at 16%, the domestic business proved to be the major driver of the performance. In the US, Sun Pharma's promising
